Liver cancer treatment after immunotherapy
This trial tests a new procedure called IRE (a way to destroy tumors) for people with liver cancer that has not responded well to initial immunotherapy. It aims to help when surgery is not possible due to the tumor's size or location.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be between 18 and 75 years old.
- You must have liver cancer that is confirmed by imaging or biopsy.
- You cannot have had prior immunotherapy or other systemic treatments for your cancer.
- Your tumor must be 5 cm or smaller, and you can have up to 5 tumors.
- The cancer must not have spread outside the liver, except for a specific type of blood clot in the liver's main vein.
- You must be in generally good health, with adequate liver, kidney, and blood cell function.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a combination of local treatments (like TACE or HAIC) with bevacizumab and an immunotherapy drug (PD-1/L1 inhibitor) for advanced liver cancer. It may be an option if you haven't had systemic therapy before or if your previous treatment stopped working.
This Phase 2 trial studies whether a combination of SBRT (focused radiation) plus tislelizumab and regorafenib can control unresectable or limited-spread liver cancer. It may help by attacking tumors in the liver and immune system to improve shrinkage and control of disease.
This trial tests a treatment called IRE (irreversible electroporation) for people with liver cancer that hasn't spread. It uses electrical pulses to destroy tumors without heat or cold, and you may qualify if you have up to 3 small tumors and are otherwise healthy enough for the procedure.
This trial tests a treatment called IRE (a type of non-thermal ablation) for colorectal cancer that has spread to the liver. It aims to see if IRE can safely and effectively treat these liver tumors, offering a possible option for patients who may not be candidates for surgery or thermal ablation.
This trial tests a combination of focused radiation (SBRT), an immunotherapy drug (adelimumab), and a targeted therapy pill (apatinib) before surgery for liver cancer. The goal is to shrink tumors enough to make surgery possible or more effective.
This trial tests a combination of liver-directed chemotherapy (HAIC) with the immunotherapy drugs atezolizumab and bevacizumab for people with liver cancer that cannot be surgically removed. It aims to see if this combination can shrink tumors and improve outcomes.
Hear when a new IRE trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.